Daclizumab approved in Canada for relapsing MS


Daclizumab, a new injectable therapy administered every four weeks, has been approved by Health Canada for the treatment of adult patients with relapsing-remitting MS who have had a poor response or tolerability to at least one prior disease-modifying therapy. The drug received approval on December 8, 2016, and will be marketed as Zinbryta. An intravenous formulation was approved two decades ago (Zenapax) as an anti-rejection drug post-transplant. Zinbryta previously received approval for MS from the U.S. FDA and the European Medicines Agency.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page